Avet Pharma Announces the Launch of Midazolam Injection

Eatontown, NJ, January, 31 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Midazolam Injection in 2mg/2mL, 25mg/5mL and 50mg/10mL strengths. This launch adds to Avet’s growing portfolio of generic injectable products. Midazolam is the AP rated generic equivalent to the anesthetic drug Versed®. It is used as an agent for preoperative sedation. According to IMS data for the twelve-months ended December 2016, the U.S. market for Midazolam injection is approximately $40 million.

Download Press Release